Metabolites Secreted by Bovine Embryos In Vitro Predict Pregnancies That the Recipient Plasma Metabolome Cannot, and Vice Versa

Enrique Gomez 1,*, Nuria Canela 2, Pol Herrero 2, Adrià Cereto 2, Isabel Gimeno 1, Susana Carrocera 1, David Martín-Gonzalez 1, Antonio Murillo 1,3 and Marta Muñoz 1

1 Centro de Biotecnología Animal, Servicio Regional de Investigación y Desarrollo Agroalimentario, 33394 Gijon, Spain; imgimeno@serida.org (I.G.); scarrocera@serida.org (S.C.);
davydmg@hotmail.com (D.M.-G.); antonionmurillovet@gmail.com (A.M.); mmunoz@serida.org (M.M.)
2 Centre for Omic Sciences, Eurecat, Centre Tecnològic de Catalunya (Joint Unit Eurecat-Universitat Rovira i Virgili), Unique Scientific and Technical Infrastructure (ICTS), 43204 Reus, Spain;
nuria.canela@eurecat.org (N.C.); pol.herrero@eurecat.org (P.H.); adria.cereto@ce.eurecat.org (A.C.)
3 Carrera de Medicina Veterinaria, Facultad de Ciencias Pecuarias, Escuela Superior Politécnica de Chimborazo, Riobamba ECO60150, Ecuador

* Correspondence: egomez@serida.org; Tel.: +34-984502010

Abstract: This work describes the use of mass spectrometry-based metabolomics as a non-invasive approach to accurately predict birth prior to embryo transfer (ET) starting from embryo culture media and plasma recipient. Metabolomics was used here as a predictive platform. Day-6 in vitro produced embryos developed singly in modified synthetic oviduct fluid culture medium (CM) drops for 24 h were vitrified as Day-7 blastocysts and transferred to recipients. Day-0 and Day-7 recipient plasma (N = 36 × 2) and CM (N = 36) were analyzed by gas chromatography coupled to the quadrupole time of flight mass spectrometry (GC-qTOF). Metabolites quantified in CM and plasma were analyzed as a function to predict pregnancy at Day-40, Day-62, and birth (univariate and multivariate statistics). Subsequently, a Boolean matrix (F1 score) was constructed with metabolite pairs (one from the embryo, and one from the recipient) to combine the predictive power of embryos and recipients. Validation was performed in independent cohorts of ETs analyzed. Embryos that did not reach birth released more stearic acid, capric acid, palmitic acid, and glycerclyl monostearate in CM (i.e., (p < 0.05, FDR < 0.05, Receiver Operator Characteristic—area under curve (ROC-AUC) > 0.669)). Within Holstein recipients, hydrocinnamic acid, alanine, and lysine predicted birth (ROC-AUC > 0.778). Asturiana de los Valles recipients that reached birth showed lower concentrations of 6-methyl-5-hepten-2-one, stearic acid, palmitic acid, and hippuric acid (ROC-AUC > 0.832). Embryonal capric acid and glycerclyl-monostearate formed F1 scores generally >0.900, with metabolites found both to differ (e.g., hippuric acid, hydrocinnamic acid) or not (e.g., heptadecanoic acid, citric acid) with pregnancy in plasmas, as hypothesized. Efficient lipid metabolism in the embryo and the recipient can allow pregnancy to proceed. Changes in phenolics from plasma suggest that microbiota and liver metabolism influence the pregnancy establishment in cattle.

Keywords: bovine; embryo; in vitro; recipient; pregnancy; metabolism

1. Introduction

Developing “a robust, non-invasive test with which to select single embryos for transfer into the uterus” remains one of the major challenges for in vitro embryo technologies [1] to predict embryo quality and pregnancy outcome [2]. The interest of identifying viable embryos increases as embryonic competence decreases, since embryo transfer (ET) with the less competent embryos means using more recipients per born calf. Furthermore, since embryo cryopreservation reduces to-term embryonic viability by triggering preg-
nancy losses at different gestational endpoints [3–8]. The interest in predicting pregnancy with cryopreserved embryos is higher than within fresh ones.

In bovine reproduction, predictive studies typically selected either embryos or recipients for pregnancy and birth, while the other factor of the pregnancy equation was assumed to be viable (the embryo) or competent (the recipient). The need for extracting information from both embryo and recipient to accurately profile pregnancy was stated almost two decades ago [8], but no solution has yet leveraged the predictive power of both sources in a single tool.

The evaluation of embryonic quality for ET requires individual assessment and minimal damage to the embryo. Thus, collection of embryonic cells by biopsy allows the investigation of chromosomal stability [9] and the expression of genes regulated in single embryos with higher competence to develop [10,11]. Biopsy is, nevertheless, invasive, and the damage done to the embryo may reduce pregnancy rates, potentially leading to misidentification of embryos with actual pregnancy potential [10,12].

In contrast to biopsy, non-invasive techniques may select competent embryos with morphology and the development stage as the most used in practice. However, these criteria are subjective, and the resultant evaluation judgements within in vitro produced (IVP) embryos are far from unanimous [8,13]. Oxygen consumption [14,15], which can be coupled with time-lapse monitoring of embryo morphology and development kinetics, was efficient in predicting pregnancy, even though sophisticated equipment is required [16,17]. The above techniques are complex, expensive, and time-consuming, and require skilled operators. Therefore, simpler and non-invasive techniques are necessary to identify developmentally competent embryos.

Within non-invasive procedures, analysis of single culture medium (CM) can identify molecules released and consumed by the embryo. Metabolites, proteins, and the cargo of extracellular vesicles (EV), as small RNAs released by the embryo, are detectable in the spent CM and are informative of embryonic traits [18–21]. However, the association of such molecules with pregnancy has been investigated mainly in human embryos [19,22,23] instead of in cattle.

Metabolomics encompasses a group of sensitive techniques for broad analysis of the whole metabolome in any species. Metabolomics can gather information from genomes and the environment for improved definition of a given phenotype. One of the most interesting applications of metabolomics is the ability to predict (as opposed to diagnose) a physiological or pathological state [24,25]. Within cattle embryos, metabolomic studies were mainly focused on predicting embryonic sex [26–29] or short-term development landmarks [30–32], while few studies predicted pregnancy endpoints [6,33].

On the recipient side, the usual selection procedures based on estrus detection, corpus luteum exploration, and/or progesterone concentration measurement exclude animals that could reach pregnancy [34–36]. Metabolomics can define the temporal receptivity for pregnancy of a particular recipient [6,33,37,38]. However, we were unable to combine the predictive potential of embryos and recipients by using Fourier transform infrared spectroscopy analysis of CM and plasma [6,33]. Other authors analyzed the endometrial gene expression of the recipient in the cycle that precedes ET using invasive procedures [10,39].

The optimal predictable gestational endpoint is birth. However, recipient biomarkers predict pregnancy more effectively at Day-62 and not at birth, in particular with vitrified/warmed (V/W) embryos [37,38]. Metabolomics, and eventually proteomics, as technologies closer to the phenotype than genomics [25,40], can better define the temporal receptivity of a particular recipient within a cycle. Developing systematic and reliable methods for recipient and embryo selection is, therefore, a challenging and novel objective for cattle ET technology, particularly if embryos are cryopreserved by vitrification. We hypothesized that the pregnancy predictions normally obtained with separate metabolomics analyses could be increased with the appropriate combination of biomarkers from embryo CM and recipient plasma. In this study, using gas chromatography coupled to the quadrupole time of flight mass spectrometry (GC-qTOF), we, for the first time, identi-
fied biomarkers in recipient plasma and embryo CM that efficiently predicted pregnancy viability by combining information from the embryo and the recipient sides.

2. Results

In the discovery study, all conditioned medium (CM) and plasma samples were analyzed, but one Day-0 plasma sample was not collected. The gas chromatography coupled to quadrupole time of flight mass spectrometry (GC-qTOF) analysis led to identification and quantification of \( N = 37 \) metabolites in CM (Supplemental Table S1) and \( N = 71 \) metabolites in plasma (Supplemental Table S2). A complete description of each ET performed in this study and its gestational trajectory is shown in Supplemental Table S3.

2.1. Breed Effects on Embryo Culture Medium and Recipient Plasma

Within discriminant analysis, the metabolomes from embryo CM (Supplementary Figure S1A,B) and Day-7 plasma (Supplemental Figure S1C,D) did not significantly differ between breeds. However, Day-0 plasma reflected close to significant differences between breeds by permutation with Partial Least Square-Discriminant Analysis (PLS-DA) on Day-0 \( (p < 0.10) \) (Supplemental Figure S1E) and appreciable separation by sparse PLS-DA (sPLS-DA) (Supplemental Figure S1F). These differences are consistent with our previous study that identified 55 regulated metabolic pathways between Asturiana de los Valles (AV) \( (N = 80 \text{ samples}) \) and Holstein \( (N = 107 \text{ samples}) \) [41].

2.2. Single Candidate Biomarker Discovery

Following the identified breed effects, candidate metabolites were analyzed as an aggregate in CM (in all samples) and separated by breed in recipient plasma from AV \( (N = 13 \text{ ETs}) \) and Holstein \( (N = 17 \text{ ETs}) \). Crossbred recipient samples \( (N = 6) \) were not considered for the breed study in plasma.

2.2.1. Culture Medium

In CM, on Day-40, no metabolite fulfilled the required statistical conditions for candidate metabolites as measured by pregnancy status, but stearic acid was identified as differentially regulated in pregnancies diagnosed at Day-62 (Table 1).

Table 1. Univariate and biomarker identification studies of candidate metabolites for pregnancy endpoints birth and day-62 in culture medium (CM) of embryos transferred with vitrified/warmed embryos (CM samples from \( N = 36 \text{ ETs} \)).

| Metabolite       | BB 1  | Day-6-E 2 | Endpoint | Day-6-E 2 | P Value | Open | P Value | Pregnant | FCh | ROC-AUC | Open | Pregnant |
|------------------|-------|------------|----------|-----------|---------|------|---------|----------|-----|---------|------|----------|
| Capric acid      | 0.364 | 0.742      | Birth    | 0.048     | 329 ± 68 | 188 ± 45 | 0.021 | 4.472 | 0.728 | 10/17 | 15/19 |
| Palmitic acid    | 0.507 | 0.341      | Birth    | 0.089     | 17,719 ± 2992 | 12,460 ± 1978 | 0.051 | 5.381 | 0.669 | 12/17 | 12/19 |
| Stearic acid     | 0.350 | 0.188      | Birth    | 0.019     | 75,827 ± 9612 | 51,951 ± 6356 | 0.016 | 5.899 | 0.743 | 13/17 | 14/19 |
| Glyceryl monoesterate | 0.406 | 0.077      | Birth    | 0.023     | 2454 ± 698 | 940 ± 468 | 0.060 | 2.829 | 0.670 | 11/17 | 11/18 |

In contrast, glyceryl monoesterate (one sample deleted as out layer 1200 x mean value), capric acid, and stearic acid concentrations were significantly lower in embryos that reached birth \( (p < 0.05) \), and palmitic acid tended to decrease (Table 1). None of those metabolites was affected by bull breed, but glyceryl monoesterate concentrations tended to differ at Day-6 between morula and blastocyst stages \( (p = 0.077) \). ROC-AUC: Receiver Operator Characteristic—area under curve.

Boxplots for all the metabolites that showed ROC-AUC > 0.650 and significant \( (p < 0.05) \) or close to significant \( (p < 0.07) \) value are shown in Figure 1A–E. These metabolites were also selected in the top frequency (%) ranking by Random Forests (RF) (Figure 1F) as candidate biomarkers.
breed, but glyceryl monostearate concentrations tended to differ at Day-6 between morula and blastocyst stages (\(p=0.077\)).

**ROC-AUC**: Receiver Operator Character—area under curve.

Boxplots for all the metabolites that showed ROC-AUC > 0.650 and significant (\(p<0.05\)) or close to significant (\(p<0.07\)) value are shown in Figure 1A–E. These metabolites were also selected in the top frequency (%) ranking by Random Forests (RF) (Figure 1F) as candidate biomarkers.

**Figure 1.** Boxplots of metabolite biomarkers of embryonic viability measured in embryo culture medium of embryos that led to pregnancy or non-pregnancy: Stearic Acid on pregnancy Day-62 (A; ROC-AUC = 0.733 [0.570–0.898]), and Stearic acid at birth (B; ROC-AUC = 0.743 [0.437–0.838]), Capric Acid at birth (C; ROC-AUC = 0.728 [0.465–0.840]), Glyceryl Monostearate at birth (D; ROC-AUC = 0.670 [0.570–0.898]), and Palmitic Acid at birth (E; ROC-AUC = 0.669 [0.533–0.870]). Black dots represent the concentrations of all samples of each metabolite scaled as Log Fold Change values. The notch indicates the 95% confidence interval around the median. The mean concentration of each group is shown by a red diamond. The optimal cut-off is indicated as a horizontal red line (i.e., the closest to the left-hand corner in the corresponding ROC-AUC). (F) represents the above and other top metabolites (Y axis) ranked by their contribution to classification accuracy in predicting birth expressed as frequency (X axis) (Random Forests multivariate classification algorithm).
2.2.2. Plasma from Holstein Recipients

Metabolites that differed between plasmas from open and pregnant Holstein recipients on Day-0 were hydrocinnamic acid (Birth and Day-40), and 2-hydroxybiphenyl and glycerol-phosphate (Day-40) (Table 2).

Table 2. Univariate analysis and biomarker identification studies (ROC-AUC) of candidate metabolites in plasma collected on Day-0 (N = 16) and Day-7 (N = 17) from Holstein recipients transferred with vitrified/warmed embryos and diagnosed at pregnancy endpoints Day 40, Day 62, and birth.

| Metabolite            | Day  | Pregnancy | Univariate Study | Biomarker Discovery Study |
|-----------------------|------|-----------|------------------|---------------------------|
|                       |      | Plasma Endpoint | p | Open | Pregnant | p | FCh | ROC-AUC | Open | Pregnant |
| Hydrocinnamic acid    | 0    | Birth      | 0.059           | 362 ± 34 | 255 ± 44 | 0.044 | 0.495 | 0.797 | 6/8  | 6/8  |
| Hydrocinnamic acid    | 0    | Day-40     | 0.012           | 400 ± 34 | 254 ± 26 | 0.005 | 0.666 | 0.900 | 5/6  | 8/10 |
| 2-hydroxybiphenyl     | 0    | Day-40     | 0.013           | 271 ± 30 | 363 ± 23 | 0.031 | −0.395 | 0.900 | 5/6  | 8/10 |
| Glycerol-phosphate    | 0    | Day-40     | 0.017           | 1315 ± 307 | 1401 ± 238 | 0.062 | −0.586 | 0.883 | 6/8  | 8/10 |
| Alanine               | 7    | Birth      | 0.065           | 1662 ± 182 | 2163 ± 172 | 0.065 | −0.357 | 0.792 | 6/8  | 6/9  |
| Lysine                | 7    | Birth      | 0.067           | 148 ± 25  | 223 ± 24  | 0.049 | −0.497 | 0.778 | 6/8  | 7/9  |
| Threonine             | 7    | Day-62     | 0.051           | 93 ± 18   | 141 ± 15  | 0.052 | −0.669 | 0.800 | 5/7  | 8/10 |

Open and pregnant: concentrations in arbitrary units (Univariate study) and samples correctly identified/total samples (Biomarker discovery study). p values: Kruskal-Wallis test or General Linear Model procedure with Bonferroni correction p < 0.05 (Univariate study) and t-test (Biomarker discovery study). Significant differences: p < 0.05. Tendency (bold) 0.05 < p < 0.07. FCh = Log Fold change. ROC-AUC: Receiver Operator Characteristic—area under curve.

In Day-7 plasma, alanine and lysine differed within pregnancies diagnosed at birth, while threonine differed on Day-62. Such metabolites were confirmed as candidate biomarkers with ROC-AUC > 0.778 and either significant (p < 0.05) or close to significant (p < 0.07) values. Boxplots of the most relevant plasma Holstein biomarkers from Day-0 plasma are shown in Figure 2A–C and frequency rankings by the Support Vector Machine (SVM) for Day-0 candidate biomarkers at gestational Day-40 and birth, and on Day-7 at birth, are shown in Figure 2D–F.

2.2.3. Plasma from AV Recipients

In Day-0 plasma, 6-methyl-5-hepten-2-one, stearic acid, and palmitic acid (at birth). Palmitic acid (at Day-62 and Day-40, same results) differed (p < 0.05) or tended to differ (0.05 < p < 0.072) (Table 3) between diagnosed open and pregnant AV recipients. In Day-7 plasma, hippuric acid differed in pregnancies diagnosed at birth, and hippuric acid, valine, N-(2-hydroxyethyl) iminodiacetic acid 2 (abbreviated as HEIDA), and dehydroascorbic acid differed in pregnancy diagnoses at Day-62 and Day-40. These metabolites were candidate biomarkers with ROC-AUC > 0.832 and significant (p < 0.05) or close to significant (p < 0.072) values.

Boxplots in Figure 3 depict the most relevant metabolite biomarkers found in AV plasma at birth on Day-0 (Figure 3A–C) and on Day-7 (Figure 3D). Within the SVM ranking of selected frequencies in Day-0 plasma at birth, stearic acid, and palmitic acid, and 6-methyl-5-hepten-2-one (Figure 3E) appeared in the top place. On Day-40 and Day-62, hippuric acid, valine, bicine, and dehydroascorbic acid were among the top 15 selected metabolites (Figure 3F).
Figure 2. Boxplots of metabolite biomarkers of pregnancy viability measured in plasma of pregnant and open Holstein recipients on Day-0 (Hydrocinnamic Acid (A) and 2-Hydroxybiphenyl (B) at pregnancy Day-40 and Hydrocinnamic Acid at birth (C)). Black dots represent the concentrations of all samples of each metabolite scaled as Log Fold Change values. The notch indicates the 95% confidence interval around the median. The mean concentration of each group is shown by a red diamond. The optimal cut-off is indicated as a horizontal red line (i.e., the closest to the left-hand corner in the corresponding ROC-AUC). Frequency rankings by a Support Vector Machine (SVM) algorithm for top biomarkers, including those of the above boxplots, are shown at gestational Day-40 on Day-0 plasma (D) and birth (E), and on Day-7 at birth (F) (1: Pregnant or birth to term recipients. 0: open recipients).
Table 3. Univariate and biomarker discovery study (ROC-AUC) of candidate metabolites at pregnancy endpoints (Day 40, Day 62, and birth) in Day-0 (N = 13) and Day-7 (N = 13) plasma of Asturiana de los Valles recipients transferred with vitrified/warmed embryos (data from Day-62 and Day-40 were the same).

| Metabolite                  | Plasma Endpoint | Univariate Study | Biomarker Discovery Study |
|-----------------------------|-----------------|------------------|---------------------------|
|                             |                 | p                | FCh | ROC-AUC | Open | Pregnant |
| Stearic acid                | 0 Birth         | 0.022            | 3668 ± 96 | 3204 ± 104 | 0.007 | 0.191 | 0.881 | 6/7 6/6 |
| Palmitic acid               | 0 Birth         | 0.007            | 2901 ± 215 | 2136 ± 221 | 0.013 | 0.367 | 0.976 | 6/7 6/6 |
| 6-methyl-5-hepten-2-one     | 0 Birth         | 0.055            | 108 ± 1.9 | 115 ± 2.0 | 0.055 | −0.078 | 0.833 | 6/7 5/6 |
| Palmitic acid               | 0 D40-D62       | 0.015            | 286 ± 17  | 223 ± 16  | 0.020 | 0.342 | 0.929 | 5/6 6/7 |
| Hippuric acid               | 7 Birth         | 0.021            | 2385 ± 144 | 1663 ± 148 | 0.071 | 0.430 | 0.857 | 5/7 5/6 |
| Hippuric acid               | 7 D40-D62       | 0.045            | 2458 ± 230 | 1839 ± 213 | 0.045 | 0.454 | 0.833 | 4/6 6/7 |
| L-Valine                    | 7 D40-D62       | 0.056            | 4254 ± 443 | 3607 ± 410 | 0.056 | 0.596 | 0.857 | 5/6 6/7 |
| N-(2-hydroxyethyl)iminodiacetic acid 2 | 7 D40-D62       | 0.022            | 10,743 ± 492 | 9150 ± 455 | 0.037 | 0.230 | 0.881 | 5/6 7/7 |
| Dehydroascorbic acid        | 7 D40-D62       | 0.034            | 1213 ± 66 | 1012 ± 49 | 0.034 | 0.302 | 0.857 | 5/6 6/7 |

Open and pregnant: concentrations in arbitrary units (Univariate study) and samples correctly identified/total samples (Biomarker discovery study). p values: Kruskal-Wallis test or GLM procedure with Bonferroni correction p < 0.05 (Univariate study) and t-test (Biomarker discovery study) significant differences: p < 0.05. Tendency (bold): 0.05 < p < 0.072. FCh = Log Fold change.

2.3. Combined Biomarker Discovery

Combinations of the embryo CM metabolites glyceryl monostearate, capric acid, palmitic acid, and stearic acid were examined by multivariate analysis using SVM, PLS-DA, and RF (Supplementary Figure S2) at birth. The algorithm providing higher predictive accuracy (PA) was PLS-DA when used in combinations of two metabolites. ROC curves deployed in Supplemental Figure S3 showed the best value combinations of pairs of metabolites. Such ROC values obtained for combined features were generally similar to or slightly lower than single ROC-AUC values for each CM metabolite shown in Table 1. Within AV recipients, the mean PA multivariate models included stearic acid, 6-methyl-5-hepten-2-one, and palmitic acid on Day-0 at birth. The best mean PA model was PLS-DA and included two metabolites, whose combinations resulted in ROC-AUC values between 0.857 and 0.897, similar to or slightly lower than the single ROC-AUC values shown in Table 3. Models in Holstein recipients included hydrocinnamic acid, 2-hydroxybiphenyl, and glycerol-phosphate on Day-40, which is the most representative pregnancy endpoint in Table 2. In this case, the best mean predictive model was RF with three metabolites (mean PA: 75%). The AUC-ROC value measured involving these three metabolites was 0.890, which is again similar to or lower than the single ROC-AUC values shown in Table 2.

2.4 F1 Score: combinations of single metabolites from CM and plasma were identified by the F1 score as potential biomarkers for pregnancy and birth. F1 scores were calculated both within aggregate and separate embryonic stages on Day-6 (morula and early blastocyst) and within separate recipient breeds. Embryonic stages on Day-6 are well-controlled, fixed factors in individual embryo culture. F1 scores based on embryonic stages are shown only in the Holstein recipient discovery group (N = 17 samples), not in the AV discovery group because its lower sample numbers (N = 13) precluded these calculations. The most robust and highly significant (p < 0.02 to p < 0.001) F1 scores identified for pregnancy and birth are shown in Table 4.
Figure 3. Boxplots of the biomarker metabolites measured in Day-0 plasma of Asturiana de los Valles recipients transferred with vitrified/warmed embryos (discovery study) as diagnosed at birth (i.e., Stearic Acid, ROC-AUC = 0.881 (0.571–1.000) (A), Palmitic Acid, ROC-AUC = 0.976 (0.786–1.000) (B), and 6-methyl-5-hepten-2-one, ROC-AUC = 0.833 (0.500–1.000) (C)), and in Day-7 plasma (Hippuric Acid, ROC-AUC = 0.857 (0.571–1.000) (D)), from open (blue boxes) and pregnant (yellow boxes). Black dots represent the concentrations of all samples of each metabolite scaled as Log Fold Change values. The notch indicates the 95% confidence interval around the median. The mean concentration of each group is shown by a red diamond. The optimal cut-off is indicated as a horizontal red line (i.e., the closest to the left-hand corner in the corresponding ROC-AUC). Frequency rankings by a Support Vector Machine (SVM) algorithm for top biomarkers, including those of the above boxplots, are shown on Day-0 plasma at birth (E), and on gestational days 40 and 62 (same biomarkers) (F) (1: Pregnant or birth to term recipients. 0: open recipients).
Table 4. Pairs of single biomarker metabolites in the embryo culture medium and plasma (Day-0 or Day-7) predict pregnancy at the indicated endpoints and within recipient breeds (AV: Asturiana de Valles, Holstein) by calculation of F1 scores within aggregate (Day-6 embryonic stages not considered) or B/M (Day-6 separate blastocyst and morula stages analyzed).

| Breed          | Embryo Culture Medium Metabolite | ROC-AUC | Recipient Plasma Metabolite | Day | ROC-AUC | Endpoint | Aggregate | B/M | p       |
|----------------|---------------------------------|---------|-----------------------------|-----|---------|----------|-----------|-----|---------|
| AV             | Capric acid                     | 0.728   | Palmitic acid               | 0   | 0.952   | Birth    | 1.000     |     | <0.001 |
| AV             | Capric acid                     | 0.728   | Stearic acid                | 0   | 0.881   | Birth    | 1.000     |     | <0.001 |
| AV             | Capric acid                     | 0.728   | Heptadecanoic acid          | 0   | 0.810   | Birth    | 0.923     | 0.002|
| AV Glyceryl-Monostearate | 0.721                       | Palmitic acid           | 0   | 0.952   | Birth    | 0.923     | 0.002|
| AV Glyceryl-Monostearate | 0.721                   | Stearic acid            | 0   | 0.881   | Birth    | 0.923     | 0.002|
| AV Glyceryl-Monostearate | 0.721                  | Heptadecanoic acid      | 0   | 0.810   | Birth    | 0.923     | 0.002|
| AV             | Capric acid                     | 0.728   | L-Valine                    | 7   | 0.762   | Birth    | 0.900     | 0.008|
| AV             | Capric acid                     | 0.728   | 2-hydroxybiphenyl          | 7   | 0.714   | Birth    | 0.923     | 0.002|
| AV             | Capric acid                     | 0.728   | N-(2-hydroxyethyl)iminodiacetic acid 2 | 7   | 0.762   | Birth    | 0.923     | 0.002|
| AV             | Capric acid                     | 0.728   | Hippuric acid               | 7   | 0.857   | Birth    | 0.857     | 0.008|
| AV             | Capric acid                     | 0.728   | Dehydroascorbic acid        | 7   | 0.738   | Birth    | 0.857     | 0.008|
| AV Glyceryl-Monostearate | 0.695                      | Palmitic acid           | 0   | **0.904** | D62     | 0.875     | 0.008|
| AV Glyceryl-Monostearate | 0.695                   | Stearic acid            | 0   | 0.733   | D62     | 0.875     | 0.008|
| AV Glyceryl-Monostearate | 0.695                  | Heptadecanoic acid      | 0   | 0.810   | D62     | 0.875     | 0.008|
| AV             | Capric acid                     | 0.662   | Stearic acid                | 0   | 0.785   | D40      | 0.933     | 0.002|
| AV             | Capric acid                     | 0.662   | Heptadecanoic acid          | 0   | 0.786   | D40      | 1.000     | <0.001|
| AV Glyceryl-Monostearate | 0.687                      | Palmitic acid           | 0   | **0.904** | D40     | 0.875     | 0.008|
| AV Glyceryl-Monostearate | 0.687                   | Stearic acid            | 0   | 0.733   | D40     | 0.875     | 0.008|
| AV Glyceryl-Monostearate | 0.687                  | Heptadecanoic acid      | 0   | 0.810   | D40     | 0.933     | 0.002|
| Holstein       | Capric acid                     | 0.728   | Hydrocinnamic acid          | 0   | 0.797   | Birth    | 0.889     | 0.933 | <0.001|
| Holstein       | Capric acid                     | 0.728   | Glycerol-phosphate          | 0   | 0.625   | Birth    | 0.842     | 0.933 | <0.001|
| Holstein       | Capric acid                     | 0.728   | Citric acid                 | 0   | 0.625   | Birth    | 0.889     | 0.941 | <0.001|
| Holstein       | Glyceryl-Monostearate           | 0.695   | Citric acid                 | 0   | 0.625   | Birth    | 0.842     | 0.889 | 0.002|
| Holstein       | Capric acid                     | 0.728   | L-Alanine                   | 7   | 0.792   | Birth    | 0.900     | 0.900 | 0.001|
| Holstein       | Capric acid                     | 0.728   | L-Threonine                 | 7   | 0.764   | Birth    | 0.900     | 0.947 | <0.001|
| Holstein       | Capric acid                     | 0.728   | Hydrocinnamic acid          | 7   | 0.583   | Birth    | 0.900     | 0.947 | <0.001|
| Holstein       | Capric acid                     | 0.728   | Glycerol-phosphate          | 7   | 0.652   | Birth    | 0.900     | 0.947 | <0.001|
| Holstein       | Glyceryl-Monostearate           | 0.695   | Hydrocinnamic acid          | 0   | 0.794   | D62      | 0.857     | 0.903 | 0.001|
| Holstein       | Capric acid                     | 0.670   | Hydrocinnamic acid          | 0   | 0.900   | D40      | 0.952     | 0.952 | <0.001|
| Holstein       | Glyceryl-Monostearate           | 0.687   | Hydrocinnamic acid          | 0   | 0.900   | D40      | 0.909     | 0.952 | <0.001|
| Holstein       | Capric acid                     | 0.670   | L-Valine                    | 7   | 0.606   | D40      | 0.917     | 0.917 | 0.002|
| Holstein       | Capric acid                     | 0.670   | L-Threonine                 | 7   | 0.757   | D40      | 0.917     | 0.957 | <0.001|
| Holstein       | Glyceryl-Monostearate           | 0.687   | L-Threonine                 | 7   | 0.757   | D40      | 0.917     | 0.917 | 0.002|

F1 scores that do not show higher values than ROC-AUC values from single metabolites are in bold.

F1 scores based on embryonic stages are shown within the Holstein discovery group (N = 16 and N = 17 sample pairs from Day-0 and Day-7, respectively), and were not possible in the AV discovery group because of lower N (N = 13 samples).

Probability values within F1 scores were calculated as chi-square Manzel-Haenszel correction. Two single biomarkers identified in CM (capric acid and glyceryl-monostearate) gave the best combinations with biomarkers in plasma. These plasma biomarkers forming the F1 score were mostly identified before in our single biomarker study (Sections 2.2.1–2.2.3) with few exceptions (e.g., heptadecanoic acid in AV, citric acid in Holstein). As hypothesized, distinguishing by embryonic stage on Day-6 generally led to a higher F1 score than with an aggregate Day-6 embryonic stage. At the same time, with few exceptions, the F1 score often showed higher predictive potential than the individual ROC-AUC value of each metabolite considered and/or aggregation of several metabolites from either embryonal or recipient origin. An example of how the F1 score works for combined biomarker calculation is given in Supplemental Table S4.
2.4. Candidate Biomarker Validation

Using a targeted biomarker approach, we analyzed the selected candidate biomarkers in an independent cohort of Holstein recipients (N = 19 ETs). Plasma samples collected on Day-0 were preferred for validation owing to the interest in anticipating the time to select ET recipients in the field by seven days. Metabolite biomarkers analyzed were chosen by their best values forming F1 scores (i.e., capric acid and glyceryl-monostearate in CM), and hydrocinnamic acid, citric acid, and hippuric acid in Day-0 plasma). Palmitic acid was discarded because its levels in CM were around the detection limit. Supplemental Table S5 shows relative concentrations of embryos transferred, grouped by Day-6 stage and culture medium as related to birth, and the major fixed effects identified. No significant differences were observed. However, the \( P \) value for F1 was significant within all metabolite combinations as measured by the Day-6 embryonic stage, as shown in Table 5.

Table 5. Targeted validation (GC-MS) at birth by F1 score (with or without separation of blastocyst and morula as Day-6 embryonic stages) of metabolite pairs selected in embryo culture medium (N = 19) and Holstein recipient Day-0 plasma (N = 19).

| Combined Metabolites | With Day-6 Embryonic Stage | Without Day-6 Embryonic Stage |
|----------------------|----------------------------|-------------------------------|
|                      | True | F1 Score | \( p \) Value | True | F1 Score | \( p \) Value |
| Capric acid          | 14/19 | 0.848 | 0.013 | ND   |
| Hydrocinnamic acid   |      |        |            |      |          |            |
| Glyceryl-monostearate| 15/19 | 0.882 | 0.005 | 14/19 | 0.848 | 0.013 |
| Hydrocinnamic acid   |      |        |            |      |          |            |
| Capric acid          | 16/19 | 0.889 | 0.002 | ND   |
| Citric acid          |      |        |            |      |          |            |
| Glyceryl-monostearate| 16/19 | 0.914 | 0.002 | ND   |
| Citric acid          |      |        |            |      |          |            |
| Capric acid          | 13/19 | 0.813 | 0.033 | ND   |
| Hippuric acid        |      |        |            |      |          |            |
| Glyceryl-monostearate| 15/19 | 0.882 | 0.005 | 14/19 | 0.848 | 0.013 |
| Hippuric acid        |      |        |            |      |          |            |

ND: Not determined because less true values were identified than any or both metabolites individually. True: samples correctly identified as pregnant (true positives) + open (true negatives)/total samples analyzed. \( p \) value analyzed by Chi-Square Mantel-Haenszel.

3. Discussion

In this work, we identified metabolites by non-invasive methods in the embryo CM that represent predictive biomarkers of pregnancy and birth in cattle. We also found candidate metabolite biomarkers in recipient plasma whose numbers were more abundant on Day-0 than Day-7, in contrast with recent \(^1\)H-NMR studies that identified all biomarkers on Day-7 [37,38]. The combined use of single metabolites from the embryo and the recipient increased the predictive power, as hypothesized, indicating that the assumption of full viability of the partner embryo or the recipient confounds pregnancy estimation [8]. Such improved predictions of the F1 score were also superior to combinations of metabolites either from the embryo or from the recipient alone. Collectively, the F1 score showed a robust tool for pregnancy prediction.

3.1. Embryo Metabolites

Non-viable embryos released higher amounts of non-esterified saturated fatty acids (NEFAs) (stearic, capric, and palmitic acids) and glyceryl-monostearate into the CM. The lipid metabolism was, therefore, highly involved in the ability of V/W embryos to reach pregnancy to term. Lipid stocks in embryonic cells consist mainly of granules of triglyceride [42,43] that decrease from the morula to the expanded blastocyst stage [44,45]. At the same time, lipolytic gene expression increases [45]. With independence of the lipid load, lipid breakdown mechanisms are conserved and active in mammalian embryos [42,46] including cattle [47] and early embryos that are able to develop in the absence of exogenous substrates (reviewed by Reference [48]). Furthermore, bovine IVP embryos can use products of beta oxidation as energy substrates [49,50] and synthesize steroids and hormones from lipids [47]. The excess of embryonic NEFA released into CM could be a protective mechanism, since high saturated FA concentrations are detrimental for oocyte development and embryo quality [51–54], whereas unsaturated fatty acids (FAs) are
protective [52,55–58]. Thus, poor quality embryos that do not reach full-term pregnancy would not be able to oxidize an excess of FAs and would release them.

Many studies have expressed the detrimental effects of lipid stored in embryonic cells to survive cryopreservation [58–60]. However, recent findings suggest that the lipid contents can be related with overall embryonic viability rather than strict survival to cryopreservation [61,62]. We observed similar evidence with V/W embryos cultured free of protein for 24 h, [44,59], whereby lipid stocks decrease and the transferred blastocysts did not undergo the high miscarriage rates shown by their counterparts produced with protein [59]. Our present results confirm this hypothesis, since the fully viable embryos were those bearing lower lipid degradation (i.e., less active lipid catabolism), as shown by the reduced FA contents in their spent media. To our knowledge, no other similar metabolomic study associated with the embryo and its viability to term in a non-invasive way.

3.2. Recipient Plasma Metabolites

Candidate biomarkers were detected at more than one pregnancy endpoint. Thus, cows that sustained birth to term showed lower concentrations of hydrocinnamic (Holstein) and hippuric (AV) acids. Such phenol-related metabolites predicted pregnancy in Day-0 plasma in Holsteins, (i.e., hydrocinnamic acid (on Day-40 and birth, and 2-hydroxybiphenyl on Day-40), and in Day-7 plasma in AV (i.e., hippuric acid, all pregnancy endpoints). In contrast, hippuric acid was found to not be pregnancy predictive in a 1H NMR study with Holstein and AV recipient plasma [37,38], which is controversial and requires further research. Ruminal microorganisms reduce forage phenolic monomers to phenyl-acids, such as hydrocinnamic acid, which is metabolized to hippuric acid in the liver [63]. Hydroxybiphenyl related compounds can be degraded in the rumen by bacteria through the biphenyl catabolic pathway [64,65]. However, increased 2-hydroxybiphenyl in pregnant recipients is surprising since it is a fungicide that would be more related to feeding than to the endogenous cow metabolism. The influence of phenolics—and the participation of ruminal microbiota—on pregnancy merit further research.

The regulation of plasma amino-acids within pregnancy prediction was generally very consistent with previous findings by 1H-NMR [37,38]. Thus, in Holsteins, L-threonine, L-alanine, L-Lysine, and 3-methyl-2-oxoalate, which is an L-isoleucine metabolite, were pregnancy predictive with fresh or V/W embryos [37]. Furthermore, L-lysine, L-alanine, and L-threonine were in the top frequencies of SVM and RF [37,38]. In agreement with our results, a similar 1H NMR study within V/W embryos in the AV breed, showed L-valine to be pregnancy predictive for Day-40/Day-62, while L-isoleucine predicted term pregnancy [38]. Such changes in L-Valine and L-Isoleucine plasma levels must be interpreted with caution, as their concentrations might be altered by dietary protein [66], lactation [67], and bacterial lipopolysaccharide [68].

Metabolites involved in lipid metabolism likely represent the major differences detected in plasma between pregnant and open recipients in this work. Holstein pregnant recipients showed higher concentrations of glycerol-3-phosphate (G3P), which controls triacylglycerol synthesis together with fatty acyl CoA, substrate availability, and insulin as a promoter [69]. In addition, the genes that regulate lipogenesis are active in non-lactating cows [69,70], and the moderate increase in G3P in Holstein recipients that were later pregnant on Day-40 points out that satisfied energy requirements sustain early pregnancy.

In AV recipients, stearic acid, palmitic acid, dehydroascorbic acid (DHA), and 6-methyl-5-hepten-2-one differed in concentration in Day-0 and Day-7 plasma between pregnant and open recipients. The increase of NEFAs in blood is associated with lipid degradation in the cow as shown within cows in negative energy balance [71–73]. Stearic and palmitic acids alter the endometrial cell function by promoting lipid deposition and pro-inflammatory gene expression [74–76]. Furthermore, as shown above within embryos, an unsaturated NEFA-rich environment is negative for embryo development and viability. Concentrations of stearic acid were lower in recipients that reached birth, and palmitic acid was lower in recipients at all pregnancy endpoints analyzed. We have already observed the
same trend in another study with Holstein recipients that become pregnant after receiving
V/W embryos [37]. In an AV study [38], 2-hydroxybutyric acid and acetone were decreased
in recipients that reached birth. These findings show the main role of lipid metabolism,
consistent with less lipid breakdown metabolites in the blood of pregnant recipients.

Another interesting metabolite is DHA, which may act through two mechanisms in
the recipient. First, as an enzyme cofactor for the synthesis of carnitine, neutralizing the
reactive oxygen species arising from FA mitochondrial metabolism [77]. Second, directly
on the embryo, by increasing E2 production, as shown in human cytotrophoblast cells [78],
through which it may have a role in pregnancy. In the cow, vitamin C requirements
can be satisfied with the ascorbic acid (AA) synthesis from glucose. AA may, in turn,
be metabolized to DHA [79]. Therefore, in our work, the lower DHA levels in pregnant AV
recipients are consistent with the lower availability of NEFA and lower need for DHA itself.

3.3. Pregnancy Prediction: Single Biomarkers

Significant fold changes within ROC-AUC values in embryos were all >2, while in
recipients were <2. Values in recipients are consistent with 1H-NMR studies [37,38]. Al-
most all biomarkers found within embryos were predictive only at birth. In contrast,
plasma biomarkers were found for every pregnancy endpoint in AV plus Holstein (9, 6,
and 7 biomarkers predicted at Day-40, Day-62, and birth, respectively). Of these, only two
biomarkers (the acids stearic and palmitic, in AV) showed clear significance at birth, ei-
ther in the univariate study or the biomarker discovery study or both, while the remaining
birth biomarkers (including all identified in Holstein) showed tendencies. Factors that
govern early pregnancy in cattle depend mainly on recipients, whose pregnancy-predictive
ability declines after Day-60 [8], and includes the critical peri-implantation period (Day-14
to Day-28) with the abundant embryo losses that hallmark recipient fertility [36]. These find-
ings are in agreement with the predictive power and timing of biomarkers found in
this study.

3.4. New Biomarker Strategies

In this study, we divided the recipient cohort by breeds, as suggested by discriminant
analyses and previous findings with 1H-NMR [37,38]. Subdividing the datasets into con-
trollable, non-random blocks improved the validation of predictions [37,38]. Accordingly,
the set of biomarkers obtained were completely different between AV and Holstein recipi-
ents. In contrast, we discovered the biomarkers within the entire embryo dataset and found
biomarker candidates valuable for “bovine embryos” notwithstanding oocyte origins,
individual bulls, and breed bulls. We consider the combined predictive value of the F1
score as the most important finding in our study. When using biomarkers from two sides
(i.e., embryo and recipient) shown in most cases, there is more predictive power at birth
than the use of each biomarker as a single predictor. This was accompanied by improved
statistical significance and predictive power within the F1 score, especially with the use
of embryonic stages (only possible within the Holstein cohort), in line with the metabolic
differences found within embryonic stages by other authors [80–83].

The F1 score also identified “hidden” biomarkers, which were not clear as single
biomarkers (i.e., with non-significant p values), demonstrating the effect of the complemen-
tary confounders when compared to working only with either embryos or recipients ([8,
this study). His is the case of heptadecanoic acid and citric acid. At the same time, the
F1 score may change the value of the single biomarkers identified, e.g., stearic acid did
not yield higher F1 scores than capric acid and glyceryl monostearate, despite the better
value of stearic acid as a single biomarker. Within the validation procedure with the F1
score, the embryonic stage permitted considerable improvement in predictive ROC-AUC
and significance, with combinations of capric acid and glyceryl-monostearate (embry-
onic) and hydrocinnamic acid, citric acid, and hippuric acid (recipient) being significant.
The impact of the lipid metabolism in long-term survival made capric acid and glyceryl
monostearate the best candidates to predict pregnancy to term, both individually and
combined with plasma metabolites within F1 scores. Curiously, embryo CM metabolites failed to predict pregnancy at Day-40 and the only discovered candidate on Day-62 and birth (stearic acid) was not validated. In contrast, within Holstein recipients, candidates were more robust on Day-40 ($p < 0.05$ values and ROC-AUC > 0.880) than at birth ($p$ tendencies and ROC-AUC < 0.800), while, within AV, all pregnancy endpoints were balanced in biomarker amounts.

We have identified candidate metabolite biomarkers that predict pregnancy to term with V/W embryos both in the embryo and the recipient. Within Holsteins, hydrocinnamic acid, alanine, and lysine predicted birth with ROC-AUC > 0.778. Beef recipients that reached birth showed lower concentrations of 6-methyl-5-hepten-2-one, stearic acid, palmitic acid, and hippuric acid (ROC-AUC > 0.832). Embryonal capric acid and glycerylmonostearate gave the highest F1 scores (generally > 0.900) with plasma metabolites found both regulated (e.g., hippuric acid, hydrocinnamic acid) and, interestingly, not regulated (e.g., heptadecanoic acid, citric acid). Within embryos, the procedure is completely non-invasive, which likely permits correct classification of viable embryos without false negatives. Within embryos and recipients, the F1 score acts as a valuable tool that avoids confounders to obscure the biomarker value of candidate metabolites. The predictive values of individual biomarkers can be re-calculated by means of inferences from the complementary biomarkers (i.e., from the recipient or from the embryo). Such a procedure will be accomplished once more abundant and accurate information from metabolites under different real scenarios is available. The F1 score is here described for first time in mammalian pregnancy, allowing significant predictions at birth, which potentially includes discarding embryos that produce miscarriage, which is a damaging and costly event in breeding. We know that biomarker selection based on Metabolomics is not a realistic choice for on-field purposes. We envision electrochemical procedures working with a very low sample volume, portable or not, and specific laboratory ELISA or enzyme-based methods for targeted biomarkers. These assays take minutes to hours and return confident and repeatable results. Selection of embryos and recipients before ET with metabolite biomarkers can be reliable, and also cost-effective, especially if high genetic merit embryos are used. Such elite embryos arise from genomics programs, which may select superior, constitutive fertile recipients [36], but cannot select a specific cycle in which a recipient will become pregnant. The use of recipients and embryos with a well-profiled viability expectation will increase pregnancy rates, and reduce the need for recipients, which will be profitable for the breeding industry.

The metabolites discovered reveal a significant influence of lipid metabolism both on the embryo and the recipient, with a probable need for balance in fatty acids to allow pregnancy to proceed to term. The nutritional effects, manifested within the transformation of dietary phenolics, may include the microbiota and subsequent metabolism in the liver as important factors in the selection of cattle recipients.

4. Materials and Methods

All reagents were purchased from SIGMA (Madrid, Spain) unless otherwise stated. Experimental workflow is described in Figure 4.
4.1. Rationale

This study analyzed the metabolomic profiles in Day-0 and Day-7 recipient plasma samples and in embryo CM. V/W embryos were transferred and recipients diagnosed as pregnant or open (i.e., non-pregnant) at specific time endpoints (Day-40, Day-62, and birth). Metabolites in CM and plasma were analyzed as a function to predict pregnancy at each pregnancy endpoint.

Biomarker discovery must be guided by principles of population science to identify the biomarkers that represent the population under scrutiny, and not only the samples studied [4,84]. Thus, discovery of recipient biomarkers for pregnancy involves using IVP embryos and recipients from varied genotypes as a way to introduce random variability in both factors determining pregnancy (i.e., embryos and recipients). Variability in embryos means including random sources, such as different bulls, oocytes from different mothers, and different embryo production systems. However, it is not feasible to adapt each biomarker to the enormous existing assortment of laboratory culture conditions. Otherwise, the risk of dependence between biomarkers and a particular embryo production system would increase [37,38]. Ideally, biomarkers that behave as predictive in highly variable populations are more valuable. However, biomarker discovery can be approached as a block strategy within non-random factors, such as recipient breed and embryo cryopreservation [37,38], which can be controlled in the laboratory. Thus, a randomized design may entail more precision within each fixed condition (i.e., block) that can be predetermined.

4.2. In Vitro Embryo Production

Oocytes were aspirated from ovaries of slaughtered cows (Matadero de Guarnizo, Cantabria, Spain). Oocytes are contained in antral follicles visible in the ovarian surface. Each punctured follicle normally renders one oocyte surrounded by cumulus cells. Such a complex must undergo a process termed in vitro maturation (IVM) by which the oocyte becomes competent to be fertilized. The procedures for ovary collection, transportation, and IVM have been recently described in detail [3]. Matured oocytes were fertilized with commercial frozen sperm from N = 10 bulls with proven fertility, which was thawed and used for in vitro fertilization (IVF, Day 0). Motile sperm were obtained by a swim-up procedure. Spermatozoa processing and IVF procedures were described [85]. Briefly, sperm were...
incubated with pre-equilibrated Sperm-TALP (Tyrode’s albumin lactate pyruvate) for 1 h. The supernatant with motile sperm was recovered and centrifuged for 7 min at 200 × g, leaving a spermatozoa pellet. IVF co-culture was performed in a fertilization medium (Fert-TALP) with heparin (10 µg/mL, Calbiochem, La Jolla, CA, USA). Spermatozoa were added at a concentration of 2 × 10^6 cells/mL in 500-µL medium per well with a maximum of 50 cumulus-oocyte complexes. IVF was accomplished by incubating oocytes and sperm cells together for 18 to 20 h at 38.7 °C in 5% CO₂ atmosphere with high humidity.

Fertilized oocytes were freed from cumulus cells by vortex and cultured in modified synthetic oviduct fluid (mSOF) containing amino acids (BME amino acids solution, 45 µL/mL, and MEM non-essential amino acids solution, 3.3 µL/mL), citrate (0.1 µg/mL), myo-inositol (0.5 µg/mL), and bovine serum albumin (BSA) (6 mg/mL) with or without 0.1% fetal calf serum (FCS). In vitro culture (IVC) was carried out at 38.7 °C, 5% CO₂, 5% O₂, 90% N₂, and saturated humidity. During IVC, embryos progress in development until reaching the blastocyst stage. In vitro, the expanded blastocyst stage is preferred for ET because of its maximal likelihood of pregnancy both as fresh and after cryopreservation. In this study, embryos were cultured in groups until Day-6. On Day-6 (143 h after the onset of fertilization), excellent and good quality (grade 1 and grade 2) morulae and early blastocysts were selected and cultured individually in 12 µL mSOF with 0.5 mg/mL polyvinyl-alcohol PVA (P8136, replacing protein supplements) under mineral oil [44]. Blastocyst development was assessed on Day-7 (168 h after fertilization), at which time expanding and fully expanded blastocysts were selected for vitrification. Embryonic stages on Day-6 and Day-7 were recorded. Readers interested in blastocyst development rates, survival to cryopreservation, differential cell counts, and lipid contents are encouraged to read Murillo et al. [44]. For pregnancy and birth rates of these embryos transferred fresh and frozen/thawed, and birth weights, please go to Gómez et al. [3].

4.3. Embryo Vitrification and Warming

Vitrification is a procedure of cryopreservation allowing embryos to remain practically unaltered for years, facilitating logistics for ET. The vitrification procedures used in this study have been described in detail [86]. Briefly, expanded blastocysts were vitrified in two steps with fibre plugs (CryoLogic Vitrification Method, CVM). Procedures were performed on a heated surface (41 °C) in a warm room (25 °C). Embryos were handled with a basic vitrification medium (VM: TCM 199-HEPES + 20% (v/v) FCS). Each blastocyst was exposed to VM with 7.5% ethylene-glycol (EG, 102466-M), 7.5% DMSO (D2650, vitrification solution-1) for 3 min, and then moved into a droplet containing VM with 16.5% EG, 16.5% DMSO, and 0.5 M sucrose (vitrification solution-2, VS2). The time spent by the embryos in VS2 (including loading) was 20 to 25 s. Samples were vitrified by touching the surface of a supercooled block placed in LN2 with a hook. Vitrified embryos held in fibre plugs were stored in closed straws in LN2 until warming, which is a necessary step to revive the embryo prior to ET. The embryos were warmed in one step by directly immersing the fibre plug end in 800 L of 0.25 M sucrose in VM, where the embryo was kept for 5 min and washed twice in VM and twice in mSOF containing 6 mg/mL BSA and 10% FCS prior to ET. Embryo morphology was evaluated prior to ET, and embryos with large fragmentation or a degenerated appearance were discarded.

4.4. Embryo Transfer and Pregnancy Diagnosis

Embryos were transferred in controlled conditions (experimental herd). For more detailed information on ET procedures and recipient traits, feeding, nutrition, and management, the readers are referred to our published work [37,38,41]. Recipient heifers from Holstein (1.84 average years old at the time of the first ET), Asturiana de los Valles (AV, 1.74 years) breeds and their crosses (1.76 years) were used. Holsteins and AV differ not only as dairy and beef breeds, respectively, but because the muscular hypertrophy (mh) phenotype present in AV cattle [87,88] is absent in Holsteins. The age/development stage of the embryo and the estrous cycle of the recipient need to be synchronized for a successful ET.
Recipients were synchronized in their oestrus cycle with an intra-vaginal progestagen device (PRID Alpha, Ceva Salud Animal, Barcelona, Spain) for 10–11 days combined with a prostaglandin F2-alpha analogue (PG, Dynolitic, Leonvet, Leon, Spain) injected 48 h before progestagen removal. Recipients selected for transfer showed either standing estrus or, in the absence of estrous signs, Day-7 progesterone (P4) values > 3.5 ng/mL, P4 fold changes Day-7/Day-0 > 8, and a healthy corpus luteum monitored by ultrasonography prior to ET.

ETs were performed with V/W Day-7 expanded blastocysts. Embryos were nonsurgically transferred to recipients under epidural anesthesia. Pregnancy was diagnosed by ultrasonography on Day 40 and on Day 62. Birth rates were monitored. Supplemental Table S6 shows all ETs performed in this study and their pregnancy rates.

4.5. Sample Collection for Metabolomics and Progesterone Analysis

Samples from embryo CM and recipient blood plasmas were collected for metabolomic analysis, always prior to the time of ET. The procedures have been described [6] with slight modifications. At the time of embryo removal from culture for vitrification on Day-7, spent CM (10 µL) and blank controls (i.e., droplets incubated without embryos) were collected, snap-frozen in LN2, and stored at −150 °C until metabolomic analysis.

Blood plasma samples from recipients were taken from coccygeal vein puncture and collected into ethylenediaminetetraacetic acid (EDTA) vacuum tubes. Blood samples were taken at fixed times on Day-0 (i.e., 96 h after PG application, 48 h after progestagen removal) and Day-7 (216 h after progestagen removal, 5 h before the ET time). Blood tubes were immediately refrigerated at 4 °C, and centrifuged at 2000 × g within 30 min of recovery. Supernatant plasma was aliquoted and stored at −150 °C until analysis.

Blood plasma P4 was measured on Day 0 and Day 7 by an enzyme-linked immunosorbent assay (ELISA) test (DRG® Progesterone ELISA, EIA-1561, DRG Diagnostics, Marburg, Germany). The test was sensitive starting from 0.5 ng/mL, and cross-reactivity from steroids other than P4 was less than 1%. Intra-assay and inter-assay coefficients of variation were 6% and 7%, respectively.

4.6. Metabolomic Analysis of Plasma and Embryo Culture Media

For metabolomic analysis in the discovery study, plasma samples of study subjects and the embryo CM were analyzed by untargeted metabolomic analyses. A GC-qTOF platform was used to cover a major number of interesting metabolites. Metabolite extraction was performed by the protein precipitation method, adding eight volumes of methanol:water (8:2 v/v) containing an internal standard mixture (succinic acid-d4, myristic acid-d27, glicerol-13C3, and D-glucose-13C6) to 100 µL of serum or 10 µL of CM. Then the samples were mixed and incubated at 4 °C for 10 min, centrifuged at 15,000 rpm, and the supernatant was evaporated to dryness and freeze dried before metabolite derivatization (metoximation and silylation). The derivatized compounds were analyzed by GC-qTOF (model 7200 of Agilent, Santa Clara, CA, USA) using the metabolomic Fiehn Method with a J&W Scientific HP5-MS (30 m × 0.25 mm, i.d., 0.25-µm film capillary column) and helium as the carrier gas under an oven program from 60 to 325 °C. Ionization was done by electronic impact (EI) with electron energy of 70 eV and operated in a full scan mode. Raw data were first examined using Unknown Analysis software from Agilent using metabolomic Fiehn library (from Agilent), which contains more than 1,400 metabolites for the screening by matching their EI mass spectrum and retention time. After putative identification of metabolites, these were semi-quantified using the internal standard (IS) response ratio across all samples. The IS ratio was calculated by the quotient between the area under the chromatographic peak of each identified metabolite and the area of their assigned IS. It is also dimensionless. This proportion is assumed to be concentration-dependent for exploratory metabolomic studies. The IS was assigned to each of the identified compounds based on their chemical similarity.
For the validation metabolomics study, the experimental procedure was as explained before, except that analytical standards for selected metabolites were used for identity confirmation and absolute quantification with internal standard calibration curves.

4.7. Experimental Design and Statistics

In this work, recipient variability was ensured with cattle from different breeds (Holstein and AV) and batches of different animals used in a three-year period (discovery study) and a subsequent two-year period (validation study). No special conditions were required other than testing free of the most prevalent ($N = 7$) infectious diseases affecting reproduction with a potential incidence in the region, healthy after clinical examination and normal after gynecological examination. Variability in embryos was based on oocytes (blind ovary collection from abattoir) fertilized with different bulls (AV ($N = 4$), Holstein ($N = 3$)). The blood plasma of recipients was collected at fixed times on Day-0 and Day-7 (4–6 h before ET). After warming, all vitrified and thawed Day-7 embryos were transferred, and no embryo or ET was discarded by any condition not described here over the experimental course of five years (Discovery and Validation studies). Pregnancy was monitored on days 40, 62, and birth. Metabolomic analysis of embryo CM and plasma was conducted as shown above to obtain relative (discovery study and part of validation study) or absolute (validation study) metabolite concentrations.

Statistical analyses of metabolite concentrations were conducted using SAS/STAT (Version 9.2, SAS Institute Inc. Cary, CA, USA) and Metaboanalyst 4.0 (Alberta, Canada) [89].

4.7.1. Analyzing Breed Effects in Embryos and Recipients

We first analyzed the influence on the metabolome of the major fixed factors’ embryo sire breed and recipient breed in the two sample collection groups ($N = 36$ from Day-7 and $N = 35$ from Day-0, as one sample from Day-0 was not collected). The embryo CM and the recipient plasma were examined with PLS-DA and sPLS-DA after data transformation with Pareto scaling (Metaboanalyst 4.0).

4.7.2. Biomarker Studies

Identification of Candidate Metabolites

Subsequent discovery studies were followed by independent analysis of single metabolites (SAS/STAT). Normality in distribution of each metabolite was analyzed (Proc UNIVARIATE). Parametric (ANOVA) and non-parametric (Kruskal-Wallis [KW]) statistics were used, as some metabolite concentrations were not normally distributed. Within CM, the effects of sire breed and embryonic stage prior to (Day-6) and after (Day-7) individual culture were investigated for single metabolites. The embryo culture in the discovery study was performed in detail with SOF + BSA ($N = 34$ samples), and $N = 2$ samples produced in SOF + BSA + FCS that completed the $N = 36$ dataset, which had no influence at any level analyzed. Subsequently, we identified DM, in accordance with the status (pregnant, non-pregnant) diagnosed at each pregnancy endpoint (Day-40, Day-62, and birth). Metabolites with significant differences ($p < 0.05$) and Bonferroni correction ($p < 0.05$) as a false discovery rate (FDR) were considered biomarker candidates.

Identification of Biomarker Candidates

Metabolite biomarker candidates were analyzed in two ways:

1. Single biomarker identification: which included a univariate study with a Receiver Operator Characteristic—area under curve (ROC-AUC) (T-Test, $p < 0.05$, ROC-AUC > 0.650) within selected metabolites at each pregnancy endpoint in each sample subset analyzed, i.e., embryo CM and plasmas (Metaboanalyst 4.0). The effects of embryonic stages on Day-6 (i.e., morula and early blastocysts) as controllable variation sources were included in this study. Subsequently, a multivariate study with ROC curve-based exploratory analysis was carried out. The classification and feature ranking methods that showed best agreement with univariate studies were RF (Mean De-
crease Accuracy—MDA— for CM metabolites) and SVM (Selected Frequency—SF—for plasma metabolites).

2. Combined biomarker identification: we analyzed the PA of multiple features with the largest ROC-AUC values within the embryo CM and recipient plasma. The “Multivariate ROC curve based exploratory analysis (Explorer)” tool from Metaboanalyst was used to test the algorithms SVM, PLS-DA, and RF. Subsequently, ROC-AUC values for multiple metabolite combinations were calculated using the “ROC curve-based model evaluation (Tester)” tool.

3. F1 score: The procedure was intended to collect information from the recipient and the embryo to potentially increase predictability. Each single biomarker identified in CM was combined with each metabolite identified in plasma to obtain an index (F1 score) that represents the aggregate predictive power of CM and plasma for each pregnancy specific endpoint. A Boolean matrix was performed for each metabolite in terms of allocation (1 = true) or not (0 = false) within the range of pregnant animals. F1 calculations were performed on the Boolean product vector of pairs of metabolites (i.e., 1 metabolite from CM and 1 metabolite from plasma/day/pregnancy endpoint). For a visual representation, see a real example in Supplemental Table S4 (i.e., CM, its corresponding plasma relative concentration, and the combined F1 score). The probability value of the F1 score was calculated by a Chi-square test.

4.7.3. Biomarker Validation

Validation studies were performed with independent samples of CM and plasma corresponding to V/W embryos transferred to different Holstein recipients (N = 19).

Supplementary Materials: The following are available online at https://www.mdpi.com/2218-1989/11/3/162/s1. Supplemental Figure S1. Partial least square discriminant analysis (PLS-DA) (1a, 1c, 1e) and Sparse-partial least square discriminant analysis (sPLS-DA) (1b, 1d, 1f) of the metabolome obtained from embryo culture medium (1a, 1b), Day-7 recipient plasma (1c, 1d), and Day-0 recipient plasma (1e, 1f). Comparisons performed were between embryos sired by Asturiana de los Valles (1) and Holstein (0) bulls, and recipients belonging to the same breeds. Close to significant separation (empirical p-values) is appreciated within Day-0 plasma samples by 100 permutation analysis for PLS-DA (p < 0.10) (1d), and appreciable separation is noted within sPLS-DA (1f). In contrast, PLS-DA analysis showed that CM (p = 0.37) and Day-7 plasma (p = 0.17) clustered together. Supplemental Figure S2. Predictive accuracy plots representative of combinations of two, three, or four features obtained using Partial Least Square—Discriminant Analysis (PLS-DA 1.1), Random Forests (RF 1.2), and Support Vector Machine (SVM 1.3). Red dots indicate the highest predictive mean accuracy obtained with each model, which corresponds to combinations of two metabolites for PLS-DA (1.1) and RF (1.2), and three metabolites for SVM (1.3). The highest mean predictive value was given by PLSDA and two metabolites (X1). Supplemental Figure S3. ROC-AUC values for specific combinations of two metabolites calculated by Partial Least Square-Discriminant analysis based on predictive accuracy plots shown in Supplemental Figure S2. 3.a: Capric acid + Stearic acid. 3.b: Capric acid + Palmitic acid. 3.c: Capric acid + Glyceryl monostearate. 3.d: Glyceryl monostearate + Palmitic acid. 3.e: Glyceryl monostearate + Stearic acid. 3.f: Stearic acid + Palmitic acid (95% confidence interval values are depicted). Supplemental Table S1. Metabolites identified in embryo culture medium. Supplemental Table S2. Metabolites identified in recipient plasma both on Day-0 and Day-7. Supplemental Table S3. Individual ETs performed and description of recipients, embryos, bull breed, and pregnancy diagnosis to term in discovery study, and validation study with Holstein recipients. Supplemental Table S4. Capacity of candidate metabolite biomarkers identified in embryo culture medium (CM) and Day-0 recipient plasma to predict pregnancy to term in Asturiana de los Valles recipients as single biomarkers and combined within an F1 score. Supplemental Table S5. Relative concentrations by targeted GC-MS (with separation of blastocyst and morula as Day-6 embryonic stages) of metabolites selected in embryo culture medium (CM) containing bovine serum albumin (BSA) or fetal calf serum (FCS) + BSA subtracted from blanks (CM with no embryos), measured in N = 19 samples corresponding to embryos transferred to Holstein recipients that differed in reaching
pregnancy to term or not. Supplemental Table S6. Embryo transfers with vitrified/warmed embryos and recipient breeds used in experiments and their pregnancy rates on Day-40, Day 62, and birth.

**Author Contributions:** Conceptualization, E.G., N.C. and M.M. Data curation, P.H. and D.M.-G. Formal analysis, E.G. and A.C. Funding acquisition, E.G. and M.M. Investigation, S.C., D.M.-G., I.G. and A.M. Methodology, E.G., M.M., P.H. and N.C. Resources, P.H., S.C. and D.M.-G. Software, A.C. Supervision, E.G. and N.C. Visualization, S.C. and D.M.-G. Writing—original draft, E.G. Writing—review & editing, S.C. and A.M. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) projects AGL2016-78997R and AGL2016-81890-REDT (Redes de Excelencia). IG is supported by MINECO BES-2017-082200. Fondo Europeo de Desarrollo Regional (FEDER). The authors are members of the COST Action 16119, In vitro 3-D total cell guidance, and fitness (Cellfit).

**Institutional Review Board Statement:** The study was approved by the Animal Research Ethics Committee of SERIDA (PROAE 26-2016, Resolución de 25 de Julio de 2016 de la Consejería de Medio Rural y Recursos Naturales) in accordance with the European Community Directive 86/609/EC.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available on reasonable request from the corresponding author. The data are not publicly available due to privacy and/or ethical concerns.

**Acknowledgments:** ASEAVA and ASCOL, for generous donation of frozen bull semen. Cooperativa de Agricultores de Gijon, for excellent support with ET and pregnancy diagnoses. ASEAVA, for plasma of some embryo-recipients housed in our experimental herd. Ann Hannigan-Breen is thanked for the English review of the manuscript.

**Conflicts of Interest:** The authors declare no competing financial interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Leese, H.J.; Guerif, F.; Allgar, V.; Brison, D.R.; Lundin, K.; Sturmey, R.G. Biological optimization, the Goldilocks principle, and how much is lagom in the preimplantation embryo. *Mol. Reprod. Dev.* **2016**, *83*, 748–754. [CrossRef]
2. Khatib, H.; Gross, N. Symposium review: Embryo survival—A genomic perspective of the other side of fertility. *J. Dairy Sci.* **2019**, *102*, 3744–3753. [CrossRef]
3. Gómez, E.; Carrocera, S.; Martín, D.; Pérez-Jámez, J.J.; Prendes, J.; Prendes, J.M.; Vázquez, A.; Murillo, A.; Gimeno, I.; Muñoz, M. Efficient one-step direct transfer to recipients of thawed bovine embryos cultured in vitro and frozen in chemically defined medium. *Theriogenology* **2020**, *146*, 39–47. [CrossRef] [PubMed]
4. Mogas, T. Update on the vitrification of bovine oocytes and in vitro-produced embryos. *Reprod. Fertil. Dev.* **2018**, *31*, 105–117. [CrossRef]
5. Sanches, B.V.; Lunardelli, P.A.; Tannura, J.H.; Cardoso, B.L.; Pereira, M.H.C.; Gaitkoski, D.; Basso, A.C.; Arnold, D.R.; Seneda, M.M. A new direct transfer protocol for cryopreserved IVF embryos. *Theriogenology* **2016**, *85*, 1147–1151. [CrossRef]
6. Muñoz, M.; Uyar, A.; Correia, E.; Diez, C.; Fernández-González, A.; Caamaño, J.N.; Martínez-Bello, D.; Trigal, B.; Humblot, P.; Ponsart, C.; et al. Prediction of pregnancy viability in bovine in vitro-produced embryos and recipient plasma with Fourier transform infrared spectroscopy. *J. Dairy Sci.* **2014**, *97*, 5497–5507. [CrossRef]
7. Xu, J.; Guo, Z.; Su, L.; Nedamhale, T.; Zhang, J.; Schenk, J.; Moreno, J.; Dinnyes, A.; Ji, W.; Tian, X.; et al. Developmental Potential of Vitrified Holstein Cattle Embryos Fertilized In Vitro with Sex-Sorted Sperm. *J. Dairy Sci.* **2006**, *89*, 2510–2518. [CrossRef] [PubMed]
8. Peterson, A.J.; Lee, R.S. Improving successful pregnancies after embryo transfer. *Theriogenology* **2003**, *59*, 687–697. [CrossRef]
9. Jakobsen, A.S.; Thomsen, P.D.; Avery, B. Few polyploid blastomeres in morphologically superior bovine embryos produced in vitro. *Theriogenology* **2006**, *65*, 780–801. [CrossRef]
10. Salilew-Wondim, D.; Hölker, M.; Rings, F.; Ghanem, N.; Ulas-Cinar, M.; Peippo, J.; Tholen, E.; Looft, C.; Schellander, K.; Tesfaye, D. Bovine pretransfer endometrium and embryo transcriptome fingerprints as predictors of pregnancy success after embryo transfer. *Physiol. Genom.* **2010**, *42*, 201–218. [CrossRef] [PubMed]
11. Ghanem, N.; Salilew-Wondim, D.; Gad, A.; Tesfaye, D.; Phatsara, C.; Tholen, E.; Looft, C.; Schellander, K.; Hoelker, M. Bovine blastocysts with developmental competence to term share similar expression of developmentally important genes although derived from different culture environments. *Reproduction* **2011**, *142*, 551–564. [CrossRef] [PubMed]
12. Zolini, A.M.; Block, J.; Rabaglino, M.B.; Tribulo, P.; Hoelker, M.; Rincon, G.; Bromfield, J.J.; Hansen, P.J. Molecular fingerprint of female bovine embryos produced in vitro with high competence to establish and maintain pregnancy†. *Biol. Reprod.* **2020**, *102*, 292–305. [CrossRef]
13. Farin, P.; Britt, J.; Shaw, D.; Slenning, B. Agreement among evaluators of bovine embryos produced in vivo or in vitro. *Theriogenology* 1995, 44, 339–349. [CrossRef]

14. Kurosawa, H.; Utsunomiya, H.; Shiga, N.; Takahashi, A.; Ihara, M.; Ishibashi, M.; Nishimoto, M.; Watanabe, Z.; Abe, H.; Kumagai, J.; et al. Development of a new clinically applicable device for embryo evaluation which measures embryo oxygen consumption. *Hum. Reprod.* 2016, 31, 2321–2330. [CrossRef]

15. Lopes, A.; Madsen, S.; Ramsing, N.; Levendahl, P.; Greve, T.; Callesen, H. Investigation of respiration of individual bovine embryos produced in vivo and in vitro and correlation with viability following transfer. *Hum. Reprod.* 2007, 22, 558–566. [CrossRef] [PubMed]

16. Sugimura, S.; Akai, T.; Imai, K. Selection of viable in vitro-fertilized bovine embryos using time-lapse monitoring in microwell culture dishes. *J. Reprod. Dev.* 2017, 63, 353–357. [CrossRef]

17. Sugimura, S.; Akai, T.; Hashiyada, Y.; Somfai, T.; Inaba, Y.; Hirayama, M.; Yamanouchi, T.; Matsuda, H.; Kobayashi, S.; Aikawa, Y.; et al. Promising System for Selecting Healthy In Vitro-Fertilized Embryos in Cattle. *PLoS ONE* 2012, 7, e36627. [CrossRef]

18. Mellisho, E.A.; Briones, M.A.; Velasquez, A.E.; Cabezas, J.; Castro, F.O.; Rodriguez-Alvarez, L. Extracellular vesicles secreted during blastulation show viability of bovine embryos. *Reproduction* 2019, 158, 477–492. [CrossRef]

19. Lindgren, K.E.; Gulen Valdir, F.; Hreinsson, J.; Holte, J.; Kárehed, K.; Sundström-Poromaa, I.; Kaihola, H.; Åkerud, H. Differences in secretome in culture media when comparing blastocysts and arrested embryos using multiplex proximity assay. *UPS J. Med. Sci.* 2018, 123, 143–152. [CrossRef] [PubMed]

20. Mellisho, E.A.; Velasquez, A.E.; Núñez, M.J.; Cabezas, J.G.; Cueto, J.A.; Fader, C.; Castro, F.O.; Rodríguez-Alvarez, L. Identification and characteristics of extracellular vesicles from bovine blastocysts produced in vitro. *PLoS ONE* 2017, 12, e0178306. [CrossRef] [PubMed]

21. Saadeldin, I.M.; Kim, S.J.; Bin Choi, Y.; Lee, B.C. Improvement of Cloned Embryos Development by Co-Culturing with Parthenotes: A Possible Role of Exosomes/Microvesicles for Embryos Paracrine Communication. *Cell. Reprogr.* 2014, 25, 16–23. [CrossRef]

22. Abu-Halima, M.; Häusler, S.; Backes, C.; Fehlmann, T.; Staib, C.; Nestel, S.; Nazarenko, I.; Meese, E.; Keller, A. Micro-ribonucleic acids and extracellular vesicles repertoire in the spent culture media is altered in women undergoing In Vitro Fertilization. *Sci. Rep.* 2017, 7, 13525. [CrossRef]

23. Pallinger, E.; Bognar, Z.; Bodis, J.; Csabai, T.; Farkas, N.; Godony, K.; Varnagy, A.; Buzas, E.; Szekeres-Bartho, J. A simple and rapid flow cytometry-based assay to identify a competent embryo prior to embryo transfer. *Sci. Rep.* 2017, 7, 39927. [CrossRef]

24. Heringstad, B.; Egger-Danner, B.; Charfeddine, N.; Fryce, J.; Stock, K.; Kofler, J.; Sogstad, A.; Holzhauer, M.; Diedler, A.; Müller, K.; et al. Invited review: Genetics and claw health: Opportunities to enhance claw health by genetic selection. *J. Dairy Sci.* 2018, 101, 4801–4821. [CrossRef]

25. Goldansaz, S.A.; Guo, A.C.; Sajed, T.; Steele, M.A.; Plastow, G.S.; Wishart, D.S. Livestock metabolomics and the livestock metabolome: A systematic review. *PLoS ONE* 2017, 12, e0177675. [CrossRef] [PubMed]

26. Rubessa, M.; Ambrosi, A.; Gonzalez-Pena, D.; Polkoff, K.M.; Wheeler, M.B. Non-invasive nuclear magnetic resonance analysis of male and female embryo metabolites during in vitro embryo culture. *Metabolomics* 2018, 14, 113. [CrossRef] [PubMed]

27. Muñoz, M.; Uyar, A.; Correia, E.; Diez, C.; Fernández-González, A.; Caamaño, J.N.; Trigal, B.; Carrocera, S.; Seli, E.; Gómez, E.; et al. Non-invasive assessment of embryonic sex in cattle by metabolic fingerprinting of in vitro culture medium. *Metabolomics* 2013, 10, 443–451. [CrossRef]

28. Gomez, E.; Carrocera, S.; Martin, D.; Herrero, P.; Canela, N.; Muñoz, M. Differential release of cell-signaling metabolites by male and female bovine embryos cultured in vitro. *Theriogenology* 2018, 114, 180–184. [CrossRef] [PubMed]

29. Gomez, E.; Muñoz, M.; Simo, C.; Ibáñez, C.; Carrocera, S.; Martín-González, D.; Cifuentes, A. Non-invasive metabolomics for improved determination of embryonic sex markers in chemically defined culture medium. *J. Chromatogr. A* 2016, 1478, 138–144. [CrossRef]

30. Nömm, M.; Porosk, R.; Pärn, P.; Kilk, M.; Porosk, R.; Pärn, P.; Kilk, M.; Soomets, U.; Kõks, S.; Jaakma, Ü. In vitro culture and non-invasive metabolic profiling of single bovine embryos. *Reprod. Fertil. Dev.* 2019, 31, 306. [CrossRef]

31. Perkel, K.J.; Madan, P. Spent culture medium analysis from individually cultured bovine embryos demonstrates metabolic differences. *Zygote* 2017, 25, 662–674. [CrossRef]

32. Dos Santos, É.C.; Martinho, H.; Annes, K.; da Silva, T.; Soares, C.A.; Leite, R.F.; Milazzotto, M.P. Raman-based noninvasive metabolic profile evaluation of in vitro bovine embryos. *J. Biomed. Opt.* 2016, 21, e75002. [CrossRef] [PubMed]

33. Muñoz, M.; Uyar, A.; Correia, E.; Ponsart, C.; Guyader-Joly, C.; Martinez-Bello, D.; Guienne, B.M.-L.; Fernández-González, A.; Diez, C.; Caamaño, J.N.; et al. Metabolomic Prediction of Pregnancy Viability in Superovulated Cattle Embryos and Recipients with Fourier Transform Infrared Spectroscopy. *BioMed Res. Int.* 2014, 2014, 1–8. [CrossRef]

34. Kanazawa, T.; Seki, M.; Ishiyama, K.; Kubo, T.; Kaneda, Y.; Sakaguchi, M.; Izaide, Y.; Takahashi, T. Pregnancy prediction on the day of embryo transfer (Day 7) and Day 14 by measuring luteal blood flow in dairy cows. *Theriogenology* 2016, 86, 1436–1444. [CrossRef]

35. Hidalgo, C.O.; Gómez, E.; Prieto, L.; Duque, P.; Goyache, F.; Fernández, L.; Fernandez, I.; Facal, N.; Diez, C. Pregnancy rates and metabolic profiles in cattle treated with propylene glycol prior to embryo transfer. *Theriogenology* 2004, 62, 664–676. [CrossRef]
36. Geary, T.W.; Burns, G.W.; Moraes, J.G.; Moss, J.I.; Denicol, A.C.; Dobbs, K.B.; Ortega, M.S.; Hansen, P.J.; Wehrman, M.E.; Nielbergs, H.; et al. Identification of Beef Heifers with Superior Uterine Capacity for Pregnancy. Biol. Reprod. 2016, 95, 47. [CrossRef]

37. Gómez, E.; Salvetti, P.; Gatien, J.; Carrocera, S.; Martín-González, D.; Muñoz, M. Blood Plasma Metabolomics Predicts Pregnancy in Holstein Cattle Transferred with Fresh and Vitrified/Warmed Embryos Produced in Vitro. J. Proteom. Res. 2020, 19, 1169–1182. [CrossRef] [PubMed]

38. Gómez, E.; Muñoz, M.; Gatien, J.; Carrocera, S.; Martín-González, D.; Salvetti, P. Metabolomic identification of pregnancy-specific biomarkers in blood plasma of BOS TAUROUS beef cattle after transfer of in vitro produced embryos. J. Proteom. 2020, 225, 103883. [CrossRef] [PubMed]

39. Mazzoni, G.; Pedersen, H.S.; Rabaglino, M.B.; Hyttel, P.; Callesen, H.; Kadarmideen, H.N. Characterization of the endometrial transcriptome in early diestrus influencing pregnancy status in dairy calf during transfer of in vitro-produced embryos. Physiol. Genomics. 2020, 52, 269–279. [CrossRef] [PubMed]

40. Guijas, C.; Montenegro-Burke, J.R.; Warth, B.; Spilker, M.E.; Siuzdak, G. Metabolomics activity screening for identifying metabolites that modulate phenotype. Nat. Biotechnol. 2018, 36, 316–320. [CrossRef] [PubMed]

41. Gómez, E.; Salvetti, P.; Gatien, J.; Muñoz, M.; Martín-González, D.; Carrocera, S.; Goyache, F. Metabolomic Profiling of Bos taurus Beef, Dairy, and Crossbred Cattle: A Between-Breeds Meta-Analysis. J. Agric. Food Chem. 2020, 68, 8732–8743. [CrossRef] [PubMed]

42. Ferguson, E.M.; Leese, H.J. A potential role for triglyceride as an energy source during bovine oocyte maturation and early embryo development. Mol. Reprod. Dev. 2006, 73, 1195–1201. [CrossRef] [PubMed]

43. Homa, S.T.; Racowsky, C.; McGaughy, R.W. Lipid analysis of immature pig oocytes. Reproduction 1986, 77, 425–434. [CrossRef] [PubMed]

44. Murillo, A.; Muñoz, M.; Martín-González, D.; Carrocera, S.; Martínez-Nistal, A.; Gómez, E. Low serum concentration in bovine embryo culture enhances early blastocyst rates on Day-6 with quality traits in the expanded blastocyst stage similar to BSA-cultured embryos. Reprod. Biol. 2017, 17, 162–171. [CrossRef]

45. Gómez, E.; Carrocera, S.; Uzbecova, S.; Martín, D.; Murillo, A.; Alonso-Guervós, M.; Goyache, F.; Muñoz, M. Protein in culture and endogenous lipid interact with embryonic stages in vitro to alter calf birthweight after embryo vitrification and warming. Reprod. Fertil. Dev. 2017, 29, 1932–1943. [CrossRef]

46. Dunning, K.R.; Cashman, K.; Russell, D.L.; Thompson, J.G.; Norman, R.J.; Robker, R.L. Beta-Oxidation Is Essential for Mouse Oocyte Developmental Competence and Early Embryo Development. Biol. Reprod. 2010, 83, 909–918. [CrossRef] [PubMed]

47. Sutton-McDowall, M.L.; Feil, D.; Robker, R.L.; Thompson, J.G.; Dunning, K.R. Utilization of endogenous fatty acid stores for energy production in bovine preimplantation embryos. Theriogenology 2012, 77, 1632–1641. [CrossRef] [PubMed]

48. Sturmey, R.G.; Reis, A.; Leese, H.J.; McEvoy, T.G. Role of Fatty Acids in Energy Provision During Oocyte Maturation and Early Embryo Development. Reprod. Domest. Anim. 2009, 44, 50–58. [CrossRef] [PubMed]

49. Gómez, E. Acetoacetate and D-beta-hydroxybutyrate as energy substrates during early bovine embryo development in vitro. Theriogenology 1997, 48, 63–74. [CrossRef]

50. Gómez, E.; Duque, P.; Díaz, E.; Facal, N.; Antolin, I.; Hidalgo, C.; Diez, C. Effects of acetoacetate and D-beta-hydroxybutyrate on bovine in vitro embryo development in serum-free medium. Theriogenology 2002, 57, 1551–1562. [CrossRef]

51. Desmet, K.L.J.; Marei, W.F.A.; Richard, C.; Sprangers, K.; Beemster, G.T.S.; Meysman, P.; Lautens, K.; Declerck, K.; Berge, W.V.; Bols, P.E.J.; et al. Oocyte maturation under lipotocic conditions induces carryover transcriptomic and functional alterations during post-hatching development of good-quality blastocysts: Novel insights from a bovine em-bryo-transfer model. Hum. Reprod. 2020, 35, 293–307. [CrossRef]

52. Marei, W.F.; De Bie, J.; Mohey-Elsaed, O.; Wydooghe, E.; Bols, P.E.; Leroy, J.L. Alpha-linolenic acid protects the developmental capacity of bovine cumulus-oocyte complexes matured under lipotocic conditions in vitro. Biol. Reprod. 2017, 96, 1181–1196. [CrossRef]

53. Desmet, K.L.J.; Van Hoeck, V.; Gagné, D.; Fournier, E.; Thakur, A.; O’Doherty, A.M.; Walsh, C.P.; Sirard, M.A.; Bols, P.E.J.; Leroy, J.L.M.R. Exposure of bovine oocytes and embryos to elevated non-esterified fatty acid concentrations: Integration of epigenetic and transcriptomic signatures in resultant blastocysts. BMC Genom. 2016, 17, 1–18. [CrossRef]

54. Van Hoeck, V.; Sturmey, R.G.; Bermejo-Alvarez, P.; Rizos, D.; Gutierrez-Adan, A.; Leese, H.J.; Bols, P.E.; Leroy, J.L. Elevated non-esterified fatty acid concentrations during bovine oocyte maturation compromise early embryo physiology. PLoS ONE 2011, 6, e23183.

55. Els, S.; Osei-Krifa, M.; Carvalho, A.V.; Bertevello, P.S.; Corbin, E.; Teixeira-Gomes, A.-P.; Lecardonnel, J.; Archilla, C.; Duranthon, V.; Labas, V.; et al. Docosahexaenoic acid mechanisms of action on the bovine oocyte-cumulus complex. J. Ovarian Res. 2017, 10, 1–14. [CrossRef]

56. Fayezi, S.; Leroy, J.L.; Novin, M.G.; Darabi, M. Oleic acid in the modulation of oocyte and preimplantation embryo development. Zygote 2017, 25, 6, 1–13. [CrossRef]

57. Thangavelu, G.; Colazo, M.; Ambrose, D.; Oba, M.; Okine, E.; Dyck, M. Diets enriched in unsaturated fatty acids enhance early embryonic development in lactating Holstein cows. Theriogenology 2007, 68, 949–957. [CrossRef] [PubMed]
58. Lowe, J.L.; Bartolac, L.K.; Bathgate, R.; Grupen, C.G. Supplementation of culture medium with L-carnitine improves the development and cryotolerance of in vitro-produced porcine embryos. Reprod. Fertil. Dev. 2017, 29, 2357–2366. [CrossRef] [PubMed]

59. Muriel-Rios, A.; Maillol, V.; Muñoz, M.; Gutiérrez-Adán, A.; Carrocera, S.; Martín-González, D.; Fernández-Buznego, A.; Gómez, E. Short- and long-term outcomes of the absence of protein during bovine blastocyst formation in vitro. Reprod. Fertil. Dev. 2017, 29, 1064–1073. [CrossRef]

60. Takahashi, T.; Inaba, Y.; Somfaï, T.; Kaneda, M.; Geshi, M.; Nagai, T.; Manabe, N. Supplementation of culture medium with L-carnitine improves development and cryotolerance of bovine embryos produced in vitro. Reprod. Fertil. Dev. 2013, 25, 589–599.

61. Paschoal, D.M.; Sudano, M.J.; Schwarz, K.R.L.; Maziero, R.R.D.; Guastali, M.D.; Crocomo, L.F.; S Bauerwein, H. Changes in tissue abundance and activity of enzymes related to branched-chain amino acid catabolism in dairy cows during early lactation. J. Anim. Sci. 1995, 73, 1766–1775. [CrossRef] [PubMed]

62. Li, P.; Li, L.; Zhang, C.; Cheng, X.; Zhang, Y.; Guo, Y.; Long, M.; Yang, S.; He, J. Palmitic Acid and Palmitate Alters the Expression of Genes Involved in the Control of Fertility in the Bovine Uterine Endometrium. J. Anim. Sci. 2018, 96, 2886–2906. [CrossRef] [PubMed]

63. Webb, L.; Sadri, H.; Von Soosten, D.; Dänicke, S.; Stehle, P.; Sauerwein, H. Changes in tissue abundance and activity of enzymes related to branched-chain amino acid catabolism in dairy cows during early lactation. J. Dairy Sci. 2019, 102, 3556–3568. [CrossRef]

64. Cremin, J.D., Jr.; McLeod, K.R.; Harmon, D.L.; Bourquin, L.D.; Fahey, G.C., Jr. Portal and hepatic fluxes in sheep and cows. Appl. Microbiol. Biotechnol. 2016, 100, 1319–1331. [CrossRef] [PubMed]

65. Cremin, J.D., Jr.; McLeod, K.R.; Harmon, D.L.; Bourquin, L.D.; Fahey, G.C., Jr. Portal and hepatic fluxes in sheep and cows. Appl. Microbiol. Biotechnol. 2016, 100, 1319–1331. [CrossRef] [PubMed]

66. Geppert, T.C.; Meyer, A.M.; Perry, G.A.; Gunn, P.J. Effects of excess metabolizable protein on ovarian function and circulating metabolites. Metabolites 2021, 10, 54.

67. Webster, L.; Sadri, H.; Von Soosten, D.; Dänicke, S.; Stehle, P.; Sauerwein, H. Changes in tissue abundance and activity of enzymes related to branched-chain amino acid catabolism in dairy cows during early lactation. J. Anim. Sci. 1995, 73, 1766–1775. [CrossRef] [PubMed]

68. Löest, C.A.; Gilliam, G.G.; Waggoner, J.W.; Turner, J.L. Post-ruminal branched-chain amino acid supplementation and intravenous lipid infusions alter blood metabolites, rumen fermentation, and nitrogen balance of beef steers. J. Anim. Sci. 2018, 96, 2886–2906. [CrossRef] [PubMed]

69. McNamara, J.; Huber, K.; Kenéz, A. A dynamic, mechanistic model of metabolism in adipose tissue of lactating dairy cattle. J. Dairy Sci. 2016, 99, 5649–5661. [CrossRef] [PubMed]

70. Drackley, J.; Donkin, S.; Reynolds, C. Major Advances in Fundamental Dairy Cattle Nutrition. J. Dairy Sci. 2006, 89, 1324–1336. [CrossRef]

71. Esposito, G.; Raffrenato, E.; Lukamba, S.D.; Adnane, M.; Irons, P.C.; Cormican, P.; Tarzada, T.; Chapwanya, A. Characterization of metabolic and inflammatory profiles of transition dairy cows fed an energy-restricted diet. J. Anim. Sci. 2020, 98, 391. [CrossRef]

72. Beam, S.W.; Butler, W.R. Effects of energy balance on follicular development and first ovulation in postpartum dairy cows. Biosci. Proc. 2019, 54, 411–424. [CrossRef]

73. Butler, W. Nutritional interactions with reproductive performance in dairy cattle. Anim. Reprod. Sci. 2000, 60-61, 449–457. [CrossRef]

74. Li, P.; Li, L.; Zhang, C.; Cheng, X.; Zhang, Y.; Guo, Y.; Long, M.; Yang, S.; He, J. Palmitic Acid and β-Hydroxybutyrate Induce Inflammatory Responses in Bovine Endometrial Cells by Activating Oxidative Stress-Mediated NF-κB Signaling. Molecules 2019, 24, 2421. [CrossRef] [PubMed]

75. Chankeaw, W.; Guo, Y.Z.; Bäge, R.; Svensson, A.; Andersson, G.; Humblot, P. Elevated non-esterified fatty acids impair survival and promote lipid accumulation and pro-inflammatory cytokine production in bovine endometrial epithelial cells. Reprod. Fertil. Dev. 2018, 30, 1770–1784. [CrossRef]

76. Waters, S.M.; Coyne, G.S.; Kenny, D.A.; MacHugh, D.E.; Morris, D.G. Dietary n-3 polyunsaturated fatty acid supplementation alters the expression of genes involved in the control of fertility in the bovine uterine endometrium. Physiol. Genom. 2012, 44, 878–888. [CrossRef] [PubMed]

77. Kepka, A.; Chojnowska, S.; Okungbowa, O.E.; Zwierz, K. The role of carnitine in the perinatal period. Dev. Period Med. 2015, 18, 417–425.

78. Wang, Y.; Tang, C.; Wu, M.; Pan, Y.; Ruan, H.; Chen, L.; Yao, H.; Zhu, H.; Wu, X. Dehydroascorbic acid taken up by glucose transporters stimulates estradiol production through inhibition of JNK/c-Jun/AP-1 signaling in JAR cells. Mol. Hum. Reprod. 2014, 20, 799–809. [CrossRef] [PubMed]

79. Rejeb, M.; Najar, T. A survey on the effect of plasma vitamin C on white blood constituents under heat stress condition for dairy cows. J. Anim. Plant. Sci. 2018, 38, 6206–6216.
80. Obeidat, Y.; Catandi, G.; Carnevale, E.; Chicco, A.J.; Demann, A.; Field, S.; Chen, T. A multi-sensor system for measuring bovine embryo metabolism. Biosens. Bioelectron. 2019, 126, 615–623. [CrossRef] [PubMed]

81. García-Herreros, M.; Simintiras, C.A.; Lonergan, P. Temporally differential protein expression of glycolytic and glycogenic enzymes during in vitro preimplantation bovine embryo development. Reprod. Fertil. Dev. 2018, 30, 1245–1252. [CrossRef]

82. Sudano, M.J.; Rascado, T.D.; Tata, A.; Belaz, K.R.; Santos, V.G.; Valente, R.S.; Mesquita, F.S.; Ferreira, C.R.; Araújo, J.P.; Eberlin, M.N.; et al. Lipidome signatures in early bovine embryo development. Theriogenology 2016, 86, 472–484.e1. [CrossRef] [PubMed]

83. Donnay, I.; Feugang, J.; Bernard, S.; Marchandise, J.; Pampfer, S.; Moens, A.; Dessy, F. Impact of adding 5.5 mM glucose to SOF medium on the development, metabolism and quality of in vitro produced bovine embryos from the morula to the blastocyst stage. Zygote 2002, 10, 189–199. [CrossRef] [PubMed]

84. Pepe, M.S.; Li, C.I.; Feng, Z. Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them. Cancer Epidemiol. Biomark. Prev. 2015, 24, 944–950. [CrossRef] [PubMed]

85. Gómez, E.; Rodríguez, A.; Muñoz, M.; Caamaño, J.N.; Carrocera, S.; Martín, D.; Facal, N.; Díez, C. Development and quality of bovine morulae cultured in serum-free medium with specific retinoid receptor agonists. Reprod. Fertil. Dev. 2008, 20, 884–891. [CrossRef]

86. Caamaño, J.; Gómez, E.; Trigal, B.; Muñoz, M.; Carrocera, S.; Martín, D.; Díez, C. Survival of vitrified in vitro–produced bovine embryos after a one-step warming in-straw cryoprotectant dilution procedure. Theriogenology 2015, 83, 881–890. [CrossRef]

87. Grobet, L.; Royo Martin, L.J.; Poncelet, D.; Pirottin, D.; Brouwers, B.; Riquet, J.; Schoeberlein, A.; Dunner, S.; Meriissier, F.; Massabanda, J.; et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat. Genet. 1997, 17, 71–74. [CrossRef]

88. McPherron, A.C.; Lee, S.-J. Double muscling in cattle due to mutations in the myostatin gene. Proc. Natl. Acad. Sci. USA 1997, 94, 12457–12461. [CrossRef] [PubMed]

89. Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J. MetaboAnalyst 4.0: Towards more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018, 46, W486–W494. [CrossRef]